Latest Information Update: 24 Apr 2007
At a glance
- Originator Endocrine Technology LLC
- Mechanism of Action CD4 antigen inhibitors; Complement factor D inhibitors; Complement factor H inhibitors; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anthrax
Most Recent Events
- 24 Apr 2007 Discontinued - Preclinical for Anthrax in USA (unspecified route)
- 22 Feb 2002 Preclinical development for Anthrax in USA (Unknown route)